Gyre Therapeutics, Inc. (GYRE)
$6.71-2.33%Close
SELLRECOVERY · day 50
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $613M
- Beta
- 4.74
- P/E (TTM)
- -33.74
- Short % float
- 11.53%
- Days to cover
- 6.9
- SI change
- +10.9%
- 1W
- -5.23%
- 1M
- +0.30%
- vs SPY 1W
- -5.09%
- vs SPY 1M
- -2.21%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on GYRE?
- LOPJLB’s latest quantitative signal on Gyre Therapeutics, Inc. (GYRE) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GYRE in?
- Gyre Therapeutics, Inc. (GYRE) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Gyre Therapeutics, Inc. (GYRE) do?
- Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials…